Literature DB >> 21799177

Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel.

Kinue Nishioka1, Motohiro Nishida, Marina Ariyoshi, Zhong Jian, Shota Saiki, Mayumi Hirano, Michio Nakaya, Yoji Sato, Satomi Kita, Takahiro Iwamoto, Katsuya Hirano, Ryuji Inoue, Hitoshi Kurose.   

Abstract

OBJECTIVE: The goal of this study was to determine whether inhibition of transient receptor potential canonical (TRPC) channels underlies attenuation of angiotensin II (Ang II)-induced vasoconstriction by phosphodiesterase (PDE) 3 inhibition. METHODS AND
RESULTS: Pretreatment of rat thoracic aorta with cilostazol, a selective PDE3 inhibitor, suppressed vasoconstriction induced by Ang II but not that induced by KCl. The Ang II-induced contraction was largely dependent on Ca(2+) influx via receptor-operated cation channels. Cilostazol specifically suppressed diacylglycerol-activated TRPC channels (TRPC3/TRPC6/TRPC7) through protein kinase A (PKA)-dependent phosphorylation of TRPC channels in HEK293 cells. In contrast, we found that phosphorylation of TRPC6 at Thr69 was essential for the suppression of Ang II-induced Ca(2+) influx by PDE3 inhibition in rat aortic smooth muscle cells (RAoSMCs). Cilostazol specifically induced phosphorylation of endogenous TRPC6 at Thr69. The endogenous TRPC6, but not TRPC3, formed a ternary complex with PDE3 and PKA in RAoSMCs, suggesting the specificity of TRPC6 phosphorylation by PDE3 inhibition. Furthermore, inhibition of PDE3 suppressed the Ang II-induced contraction of reconstituted ring with RAoSMCs, which were abolished by the expression of a phosphorylation-deficient mutant of TRPC6.
CONCLUSIONS: PKA-mediated phosphorylation of TRPC6 at Thr69 is essential for the vasorelaxant effects of PDE3 inhibition against the vasoconstrictive actions of Ang II.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21799177     DOI: 10.1161/ATVBAHA.110.221010

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 2.  Transient receptor potential canonical 7: a diacylglycerol-activated non-selective cation channel.

Authors:  Xuexin Zhang; Mohamed Trebak
Journal:  Handb Exp Pharmacol       Date:  2014

Review 3.  Transient receptor potential channels in the vasculature.

Authors:  Scott Earley; Joseph E Brayden
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

4.  TRPC6 regulates phenotypic switching of vascular smooth muscle cells through plasma membrane potential-dependent coupling with PTEN.

Authors:  Takuro Numaga-Tomita; Tsukasa Shimauchi; Sayaka Oda; Tomohiro Tanaka; Kazuhiro Nishiyama; Akiyuki Nishimura; Lutz Birnbaumer; Yasuo Mori; Motohiro Nishida
Journal:  FASEB J       Date:  2019-06-04       Impact factor: 5.191

5.  TRPC3 participates in angiotensin II type 1 receptor-dependent stress-induced slow increase in intracellular Ca2+ concentration in mouse cardiomyocytes.

Authors:  Yohei Yamaguchi; Gentaro Iribe; Toshiyuki Kaneko; Ken Takahashi; Takuro Numaga-Tomita; Motohiro Nishida; Lutz Birnbaumer; Keiji Naruse
Journal:  J Physiol Sci       Date:  2017-01-19       Impact factor: 2.781

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Molecular determinants for cardiovascular TRPC6 channel regulation by Ca2+/calmodulin-dependent kinase II.

Authors:  Juan Shi; Naomi Geshi; Shinichi Takahashi; Shigeki Kiyonaka; Jun Ichikawa; Yaopeng Hu; Yasuo Mori; Yushi Ito; Ryuji Inoue
Journal:  J Physiol       Date:  2013-03-25       Impact factor: 5.182

Review 8.  In pursuit of small molecule chemistry for calcium-permeable non-selective TRPC channels -- mirage or pot of gold?

Authors:  Robin S Bon; David J Beech
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

9.  Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2).

Authors:  David Chiluiza; Sneha Krishna; Valérie A Schumacher; Johannes Schlöndorff
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

10.  TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy.

Authors:  Tsukasa Shimauchi; Takuro Numaga-Tomita; Tomoya Ito; Akiyuki Nishimura; Ryosuke Matsukane; Sayaka Oda; Sumio Hoka; Tomomi Ide; Norimichi Koitabashi; Koji Uchida; Hideki Sumimoto; Yasuo Mori; Motohiro Nishida
Journal:  JCI Insight       Date:  2017-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.